good news balance sheet strength vivagel in RoW (already No.1 for BV treatment in Australia which gives a glimpse to the future in other countries) DEP progress continues to be outstanding and current enrolled patients are continuing to be treated. AZD continuing with trial with no issues reported.
Bad news COVID - limited new Dep patients being enrolled which may delay trials Vivagel in the US remains at a stalemate. No likely short term share market catalyst
It's disappointing to see the COVID related delays but these are temporary and out of managements control. I wanted an update on these topics and they provided it. It's still unclear if COVID will impact the timing of DEP Doc phase II, but I expect it is very hard for SPL to estimate this (hence why the statement remains a bit ambiguous). Overall very pleased.
SPL Price at posting:
89.5¢ Sentiment: Hold Disclosure: Held
